 Rocket recently released impressive data for their gene therapy candidate for Danon Disease, RP-A501. The data demonstrated that RP-A501 was able to improve some of the hallmark metrics and symptoms. Rocket is gearing up for a potential commercial launch. The company is working on building out a new HQ with RD and commercial capabilities. 